Scientists have developed a totally implantable cochlear implant that delivers hearing performance comparable to conventional devices while improving quality of life and eliminating the need for external components.
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine) – Psychedelic Alpha
Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients with Cognitive Impairment Associated with Schizophrenia DMX-1002 (Ibogaine)